S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Bank Accounts: Frozen! (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
"Prepare for Five Years of Famine" (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
"Prepare for Five Years of Famine" (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
NASDAQ:DBVT

DBV Technologies - DBVT Stock Forecast, Price & News

$1.58
-0.03 (-1.86%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.56
▼
$1.66
50-Day Range
$1.28
▼
$1.73
52-Week Range
$1.08
▼
$3.43
Volume
30,957 shs
Average Volume
35,601 shs
Market Capitalization
$297.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.38

DBV Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
240.2% Upside
$5.38 Price Target
Short Interest
Healthy
0.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of DBV Technologies in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.91) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

763rd out of 1,005 stocks

Biological Products, Except Diagnostic Industry

130th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

DBVT stock logo

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Stock News Headlines

March 24, 2023 | finance.yahoo.com
Ordinary and Extraordinary General Meeting of April 12, 2023
March 23, 2023 | americanbankingnews.com
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com
March 26, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 19, 2023 | americanbankingnews.com
Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $6.67
March 13, 2023 | finance.yahoo.com
DBV Technologies Update
March 7, 2023 | finanznachrichten.de
DBV Technologies S.A.: DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 - 7 Years Old
March 7, 2023 | finance.yahoo.com
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
March 7, 2023 | finance.yahoo.com
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
March 26, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 4, 2023 | finanznachrichten.de
DBV Technologies S.A.: DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
March 4, 2023 | benzinga.com
DBV Technologies Stock (NASDAQ:DBVT), Guidance and Forecast
March 3, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: DBV Technologies SA – American (DBVT), Veru (VERU)
March 3, 2023 | finanznachrichten.de
DBV Technologies S.A.: DBV Technologies Reports Full Year 2022 Financial Results and Business Update
March 3, 2023 | msn.com
DBV Technologies GAAP EPS of -$1.24, revenue of $4.8M
March 3, 2023 | finance.yahoo.com
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
March 3, 2023 | finance.yahoo.com
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
March 1, 2023 | benzinga.com
Earnings Preview: DBV Technologies
March 1, 2023 | benzinga.com
Earnings Preview: DBV Technologies
February 27, 2023 | finance.yahoo.com
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
February 23, 2023 | finanznachrichten.de
DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
February 21, 2023 | finance.yahoo.com
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
January 4, 2023 | finance.yahoo.com
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022
December 24, 2022 | ca.finance.yahoo.com
DBV Technologies S.A. (DBVT)
December 23, 2022 | finance.yahoo.com
DBV Technologies Shares Jumps As FDA Lifts Partial Hold On Pivotal Trial For Peanut Allergy Patch
December 23, 2022 | msn.com
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022 | seekingalpha.com
DBV stock soars 30% as FDA lifts partial hold on phase 3 trial of peanut allergy patch
December 23, 2022 | finance.yahoo.com
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Company Calendar

Last Earnings
8/01/2021
Today
3/25/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBVT
CUSIP
N/A
CIK
1613780
Web
www.dbv-technologies.com
Phone
(315) 542-7878
Fax
33-1-43-26-10-83
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.38
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+240.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,270,000.00
Net Margins
-778.60%
Pretax Margin
-777.38%
Return on Equity
-52.54%
Return on Assets
-42.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.56
Quick Ratio
7.56

Sales & Book Value

Annual Sales
$4.84 million
Price / Sales
61.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.03 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
188,270,000
Free Float
187,144,000
Market Cap
$297.47 million
Optionable
Optionable
Beta
1.23

Key Executives

  • Daniel Tassé
    Chief Executive Officer & Executive Director
  • Sébastien Robitaille
    Chief Financial Officer
  • Pharis Mohideen
    Chief Medical Officer
  • Pascal Wotling
    Chief Technical Operations & Quality Officer
  • Pascale Ehouarn
    Chief Engineering, Manufacturing & Supply Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DBVT shares.
View DBVT analyst ratings or view top-rated stocks.

What is DBV Technologies' stock price forecast for 2023?

5 analysts have issued twelve-month price objectives for DBV Technologies' stock. Their DBVT share price forecasts range from $1.50 to $10.00. On average, they anticipate the company's stock price to reach $5.38 in the next year. This suggests a possible upside of 240.2% from the stock's current price.
View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2023?

DBV Technologies' stock was trading at $1.53 at the beginning of 2023. Since then, DBVT stock has increased by 3.3% and is now trading at $1.58.
View the best growth stocks for 2023 here.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our DBVT earnings forecast.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings results on Sunday, August, 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.36. The firm had revenue of ($1.49) million for the quarter, compared to the consensus estimate of $3.53 million. DBV Technologies had a negative net margin of 778.60% and a negative trailing twelve-month return on equity of 52.54%.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Braidwell LP (6.43%), VR Adviser LLC (4.94%), RA Capital Management L.P. (1.04%), Boxer Capital LLC (0.77%), Millennium Management LLC (0.46%) and Morgan Stanley (0.26%).

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $1.58.

How much money does DBV Technologies make?

DBV Technologies (NASDAQ:DBVT) has a market capitalization of $297.47 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 3/26/2023 by MarketBeat.com Staff